Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Many Bright Ideas Technologies Inc V.MBI.H

Alternate Symbol(s):  MBGNF

Healthcare Biotechnology
Many Bright Ideas Technologies Inc. is a Canada-based company. The Company is focused on commercializing alternative non-medical technologies. The Company has not generated any revenue.


TSXV:MBI.H - Post by User

Many Bright Ideas Technologies Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by delooutchieon Oct 21, 2013 5:19pm
175 Views
Post# 21834978

daté du 9 sept 2013

daté du 9 sept 2013

Additionally, in 2013 Precision plans to release two new genomic products that examine a patients tumor at the molecular level in order to garner information about a patient's individual disease and potentially inform effective treatment options, under the GeneFx(TM) brand. For more information, visit www.precisiontherapeutics.com.

(1)Kennedy RD, Bylesjo M, Kerr P, Davison T Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. J Clin Oncol.(2011 Dec 10; 29(35):4620-6. Doi: 10.1200/JCO.2011.35.4498. Epub 2011 Nov 7.) https://www.ncbi.nlm.nih.gov/pubmed/22067406

SOURCE: Precision Therapeutics Inc.




            

                
            

            
        

    


    

        

            

                
                Bullboard Posts
                
            

        

    


    

        

            
        

    






    
    



        






        

            
                

                    



    

        
            

                






    
    

        

    






    Dealroom for high-potential pre-IPO opportunities